Format

Send to

Choose Destination
Clin Pharmacol Ther. 2007 Dec;82(6):740-4. Epub 2007 Oct 31.

MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?

Author information

1
Novartis Vaccines and Diagnostics Inc., Siena, Italy. derek.ohagan@novartis.com

Abstract

The MF59 adjuvant has been included in a licensed influenza vaccine for a decade. Hence, we have a significant amount of clinical data to establish its potency and safety. We can now reassess our early preclinical studies and determine whether or not they were useful to predict human responses. The main lesson learned is that mouse models can be valuable, but one must ask the right questions and the models must be used appropriately.

PMID:
17971820
DOI:
10.1038/sj.clpt.6100402
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center